1. Home
  2. EARN vs TNYA Comparison

EARN vs TNYA Comparison

Compare EARN & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

N/A

Current Price

$4.42

Market Cap

200.3M

Sector

Real Estate

ML Signal

N/A

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

N/A

Current Price

$0.74

Market Cap

178.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EARN
TNYA
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.3M
178.5M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
EARN
TNYA
Price
$4.42
$0.74
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.38
$5.33
AVG Volume (30 Days)
566.3K
5.2M
Earning Date
03-04-2026
03-11-2026
Dividend Yield
22.12%
N/A
EPS Growth
N/A
54.96
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.69
N/A
Revenue Next Year
$19.57
$1,456.12
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$0.36
52 Week High
$6.08
$2.35

Technical Indicators

Market Signals
Indicator
EARN
TNYA
Relative Strength Index (RSI) 30.92 47.51
Support Level N/A $0.61
Resistance Level $5.36 $0.75
Average True Range (ATR) 0.13 0.10
MACD -0.01 -0.01
Stochastic Oscillator 16.00 33.90

Price Performance

Historical Comparison
EARN
TNYA

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: